ArticleTranslational cancer research2026
Investigating the material basis and molecular mechanisms of
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) is among the most prevalent forms of thyroid cancer. Traditional Chinese medicine (TCM) has been widely employed in the management of PTC, with Methods: The impact of OD on PTC cells was assessed using a variety of assays, including cell viability, colony formation, acridine orange/ethidium bromide (AO/EB) staining, and transwell assays. Potential targets and downstream pathways were explored through network pharmacology and molecular docking analyses. Protein and gene expression levels were determined using western blotting assays. Results: OD demonstrated significant inhibitory effects on the biological functions of PTC cells. Through network analysis, 7 targets and 3 active compounds (stigmasterol, β-sitosterol, or poriferasterol) associated with OD's intervention in PTC were identified. Furthermore, correlation analysis revealed a significant positive association with the central gene involved in OD's anti-PTC effects. OD and its active compounds also modulated the phosphorylation of proteins related to the PI3K-AKT pathways, underscoring its anti-PTC efficacy. Conclusions: OD and its active compounds suppress the biological functions of PTC by modulating the phosphorylation of proteins associated with the PI3K-AKT pathway. These findings suggest that OD may inhibit PTC progression by targeting the PI3K-AKT pathway, offering potential adjuvant therapeutic value for PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.